Increlex Tercica, Inc. - Treatment for Short Stature Caused by Primary IGF-1 Deficiency
Increlex contains human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology. Increlex is indicated for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.Posted: August 2005
Related articles
- Tercica Addresses Citizen Petition Filed by Insmed - August 17, 2005
- Tercica Announces Insmed Files Citizen Petition with the FDA to Deny Approval of Increlex NDA - August 14, 2005
- FDA Accepts Tercica's Increlex New Drug Application With Priority Review for the Treatment of Short Stature - May 2, 2005
- Tercica Submits New Drug Application for Increlex as a Treatment for Short Stature Caused by Primary IGF-1 Deficiency - February 28, 2005
Increlex (mecasermin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.